2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

antitumor drug

" in MedChemExpress (MCE) Product Catalog:

196

Inhibitors & Agonists

7

Screening Libraries

15

Fluorescent Dyes

15

Biochemical Assay Reagents

6

Peptides

19

Inhibitory Antibodies

15

Natural
Products

9

Isotope-Labeled Compounds

12

Oligonucleotides

3

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99045
    Sacituzumab
    4 Publications Verification

    HRS7; hRS7

    		 ADC Antibody TROP2 Cancer
    Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
    Sacituzumab
  • HY-15579
    MMAF
    Maximum Cited Publications
    8 Publications Verification

    Monomethylauristatin F

    		 Microtubule/Tubulin ADC Payload Cancer
    MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .
    MMAF
  • HY-P9921
    Trastuzumab emtansine
    5+ Cited Publications

    Ado-Trastuzumab emtansine; PRO132365; T-DM 1

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (HY-19792). Trastuzumab emtansine can be used for the research of advanced breast cancer .
    Trastuzumab emtansine
  • HY-P9985
    Disitamab vedotin
    5 Publications Verification

    RC48

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity .
    Disitamab vedotin
  • HY-P9921A
    Trastuzumab emtansine (solution)
    Maximum Cited Publications
    6 Publications Verification

    Ado-Trastuzumab emtansine (solution); PRO132365 (solution); T-DM 1 (solution)

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer .
    Trastuzumab emtansine (solution)
  • HY-N2493
    Lawsone
    2 Publications Verification

    		 Fungal Apoptosis Infection Cancer
    Lawsone is an orally active naphthoquinone dye that can be isolated from the leaves of Lawsonia inermis. Lawsone can induce apoptosis. Lawsone has antibacterial, antitumor and antioxidant activities. Lawsone can be used in anti-tumor drug research .
    Lawsone
  • HY-112786
    MC-Val-Cit-PAB-MMAF
    5 Publications Verification

    Vc-MMAF

    		 Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF (HY-15579), linked via cathepsin cleavable MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB-MMAF shows antitumor activity .
    MC-Val-Cit-PAB-MMAF
  • HY-15582
    Auristatin E

    		Microtubule/Tubulin ADC Payload Cancer
    Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .
    Auristatin E
  • HY-152963
    Tisotumab vedotin

    		Antibody-Drug Conjugates (ADCs) Inflammation/Immunology Cancer
    Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer .
    Tisotumab vedotin
  • HY-19474
    Maytansinol

    Ansamitocin P-0

    		 Microtubule/Tubulin ADC Payload Apoptosis Cancer
    Maytansinol (Ansamitocin P-0) is a derivative of Maytansine. Maytansinol can inhibit tubulin polymerization and induce apoptosis. Maytansinol has antitumor activity. Maytansinol can be used in cancer drug research .
    Maytansinol
  • HY-171135
    Cetuximab MMAE

    		Antibody-Drug Conjugates (ADCs) EGFR Microtubule/Tubulin Cancer
    Cetuximab MMAE is an antibody-drug conjugate (ADC) consisting of the EGFR-targeting humanized monoclonal antibody Cetuximab (HY-P9905) conjugated to VcMMAE (HY-15575). Cetuximab MMAE exhibits antitumor activity .
    Cetuximab MMAE
  • HY-P99045A
    Sacituzumab (powder)

    		ADC Antibody TROP2 Cancer
    Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
    Sacituzumab (powder)
  • HY-P99101
    Vobramitamab

    AEX-4089; MGC026 antibody

    		 ADC Antibody Cancer
    Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .
    Vobramitamab
  • HY-W011556
    N,N,N',N'-Tetramethylchloroformamidinium hexafluorophosphate

    TCFH

    		 Drug Isomer Cancer
    N,N,N',N'-Tetramethylchloroformamidinium hexafluorophosphate (TCFH) is a powerful coupling and derivatizing reagent for ester prodrug synthesis. N,N,N',N'-Tetramethylchloroformamidinium hexafluorophosphate can be used for antitumor drugs before medicine research .
    N,N,N',N'-Tetramethylchloroformamidinium hexafluorophosphate
  • HY-141606
    Anetumab ravtansine

    BAY 94-9343

    		 Microtubule/Tubulin Antibody-Drug Conjugates (ADCs) Cancer
    Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .
    Anetumab ravtansine
  • HY-P10128
    GE11
    1 Publications Verification

    		 Biochemical Assay Reagents Inflammation/Immunology
    GE11 is a active peptide and combines with colloidal drug delivery systems as smart carriers for antitumor drugs and can be used for cancer study .
    GE11
  • HY-15579A
    MMAF hydrochloride
    Maximum Cited Publications
    8 Publications Verification

    Monomethylauristatin F hydrochloride

    		 Microtubule/Tubulin ADC Payload Cancer
    MMAF (Monomethylauristatin F) hydrochloride is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .
    MMAF hydrochloride
  • HY-141607
    Indatuximab ravtansine

    BT-062; nBT062-DM4

    		 Antibody-Drug Conjugates (ADCs) Bacterial Cancer
    Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities .
    Indatuximab ravtansine
  • HY-79490
    Ac-Exatecan

    		ADC Payload Topoisomerase Cancer
    Ac-Exatecan is acetylation-modified Exatecan (HY-13631). Exatecan is a common toxin component in ADC preparation (ADC cytotoxin) and an inhibitor of DNA topoisomerase I (IC50 = 2.2 μM). Exatecan has antitumor activity. Exatecan can be used as a payload for ADC. Exatecan is effective against P-glycoprotein mediated multi-drug resistant cells .
    Ac-Exatecan
  • HY-W012531
    2-Hydroxycinnamic acid
    1 Publications Verification

    		 HIV SARS-CoV Endogenous Metabolite Bacterial Infection Neurological Disease Inflammation/Immunology Cancer
    2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against Staphylococcus aureus and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of HIV/SARS-CoV S pseudovirus with an IC50 of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity .
    2-Hydroxycinnamic acid
  • HY-168489
    OBI-992 drug-linker

    		Drug-Linker Conjugates for ADC Cancer
    OBI-992 drug-linker is a drug-linker conjugate composed of a TOP I inhibitor Exatecan (HY-13631) and a linker. OBI-992 drug-linker exhibits antitumor property in mouse models and can be used for synthesis of ADC OBI-992 .
    OBI-992 drug-linker
  • HY-144880
    SC209

    3-Aminophenyl Hemiasterlin

    		 ADC Payload Microtubule/Tubulin P-glycoprotein Cancer
    SC209 (3-Aminophenyl Hemiasterlin) is a 3-aminophenyl hemiasterlin derivative that serves as a cytotoxin for ADCs, targeting tubulin. SC209 has reduced potential for drug efflux via P-glycoprotein 1 drug pump compared with other tubulin-targeting payloads. SC209 exhibits antitumor activity and can be used in the synthesis of ADC molecules .
    SC209
  • HY-128753
    D-Lyxose

    		Endogenous Metabolite Drug Intermediate Metabolic Disease
    D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose with significant potential for pharmaceutical synthesis. D-Lyxose serves as a starting material for antitumor agents (such as α-galactosylceramide-based immunostimulants). D-Lyxose acts as a precursor for L-nucleoside analogs used in the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars (such as L-ribose) .
    D-Lyxose
  • HY-W007466
    Cyclohexane-1,3-dione
    1 Publications Verification

    		 Drug Intermediate Cancer
    Cyclohexane-1,3-dione is a drug intermediate, and its derivatives can exhibit significant tyrosine kinase inhibitory activity and anti-tumor activity .
    Cyclohexane-1,3-dione
  • HY-15579B
    MMAF sodium
    Maximum Cited Publications
    8 Publications Verification

    Monomethylauristatin F sodium

    		 Microtubule/Tubulin ADC Payload Cancer
    MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .
    MMAF sodium
  • HY-145627
    Ozuriftamab vedotin

    BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC

    		 Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .
    Ozuriftamab vedotin
  • HY-139018A
    TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride

    		Drug-Linker Conjugates for ADC Cancer
    TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride (compound 9) is a drug-linker conjugates for ADC with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the non-cleavable ADC linker hydroxy-PEG10-acid (HY-133307) .
    TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride
  • HY-141602
    Pinatuzumab vedotin

    anti-CD22-vc-MMAE; DCDT2980S

    		 Antibody-Drug Conjugates (ADCs) CD22 Microtubule/Tubulin Cancer
    Pinatuzumab vedotin, an antibody-drug conjugate (ADC), is a CD22 humanized monoclonal antibody Pinatuzumab (HY-P99230) conjugated to VcMMAE (HY-15575). Pinatuzumab vedotin has antitumor activities .
    Pinatuzumab vedotin
  • HY-148128
    TAM470

    		Microtubule/Tubulin ADC Payload Cancer
    TAM470 is a novel cytolysin, inhibiting tubulin polymerization and microtubule depolymerization. TAM470 can be used in the synthesis of OMTX705 as payload molecule, OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs) with antitumor activity .
    TAM470
  • HY-139018
    TLR7/8 agonist 4 hydroxy-PEG10-acid

    		Drug-Linker Conjugates for ADC Cancer
    TLR7/8 agonist 4 hydroxy-PEG10-acid (compound 9) is a drug-linker conjugates for ADC with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the non-cleavable ADC linker hydroxy-PEG10-acid (HY-133307) .
    TLR7/8 agonist 4 hydroxy-PEG10-acid
  • HY-101150
    DGN462

    		DNA Alkylator/Crosslinker ADC Payload Cancer
    DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML). DGN462 can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .
    DGN462
  • HY-171508
    Mal-PNU-159682

    		Drug-Linker Conjugates for ADC Cancer
    Mal-PNU-159682 is a Drug-Linker Conjugates for ADC, composes of ADC linker (maleimide) and ADC cytotoxin PNU-159682 (HY-16700), and has anti-tumor activity .
    Mal-PNU-159682
  • HY-128871
    VCP-Eribulin

    		Drug-Linker Conjugates for ADC Cancer
    VCP-Eribulin is a bioactive molecule-linker conjugate designed for ADCs (Drug-Linker Conjugates for ADC), formed by conjugating an ADC linker (VCP) with Eribulin (HY-13442). Eribulin is a unique microtubule inhibitor exhibiting antitumor activity. VCP-Eribulin can be utilized for antibody conjugation .
    VCP-Eribulin
  • HY-171489
    Mal-VC-PAB-EDA-N-Ac-Calicheamicin

    		Drug-Linker Conjugates for ADC Cancer
    Mal-VC-PAB-EDA-N-Ac-Calicheamicin is a Drug-Linker Conjugate for ADC with potent antitumor activity. Mal-VC-PAB-EDA-N-Ac-Calicheamicin consists of ADC toxin Calicheamicin (HY-19609) and a linker. Mal-VC-PAB-EDA-N-Ac-Calicheamicin can be used for synthesis of ADC, PF-06647263 (HY-111965) .
    Mal-VC-PAB-EDA-N-Ac-Calicheamicin
  • HY-178819
    NM-001

    		Integrin Drug Intermediate Cancer
    NM-001 is a theranostic prodrug that targets ανβ3 integrin. NM-001 consists of cRGD and GFLG peptides, a DCM fluorophore and Chlorambucil (HY-13593). NM-001 internalizes into lysosomes of tumor cells via the cRGD peptide, and generates NM-002 (HY-178820) and Chlorambucil through intracellular cleavage at the GFLG peptide by overexpressed Cathepsin B (CTSB). NM-001 exhibits green fluorescence under physiological conditions, and converts to NIR fluorescence by CTSB activation. NM-001 has significant antitumor activity with low toxicity in HeLa cell xenografts mouse models. NM-001 can be used for real-time drug release monitoring research .
    NM-001
  • HY-174277
    Antitumor agent-203

    		ADC Payload Topoisomerase Cancer
    Antitumor agent-203 (例7) is a derivative of Exatecan (DX-8951) (HY-13631) and can be used to prepare antibody-drug conjugates (ADCs), as the ADC Cytotoxin .
    Antitumor agent-203
  • HY-128753S6
    D-Lyxose-d

    		Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate Metabolic Disease
    D-Lyxose-d is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .
    D-Lyxose-d
  • HY-144497
    HE-S2

    		PD-1/PD-L1 Toll-like Receptor (TLR) Drug-Linker Conjugates for ADC Infection Cancer
    HE-S2 is an antibody-drug conjugate triggering a potent antitumor immune response. HE-S2 acts by blocking the PD-1/PD-L1 interaction and activating the Toll-like receptor 7/8 (TLR7/8) signaling pathway. HE-S2 has remarkable antitumor activity .
    HE-S2
  • HY-P99733
    Mipasetamab

    		ADC Antibody TAM Receptor Cancer
    Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity .
    Mipasetamab
  • HY-147021
    MC-Val-D-Cit-PAB-PNP

    		ADC Linker Cancer
    MC-Val-D-Cit-PAB-PNP is a cleavable peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs). MC-Val-D-Cit-PAB-PNP contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody and a p-nitrophenol (PNP) group that allows the peptide to be linked to antitumor compounds.
    MC-Val-D-Cit-PAB-PNP
  • HY-164107
    Auristatin S

    		ADC Payload Microtubule/Tubulin Cancer
    Auristatin S is an Auristatin payload with potent antitumor activity. Auristatin S attenuates bystander activity with improved off-target toxicity. Auristatin S has excellent tolerability in Karpas/KarpasBVR cell models. Auristatin S can be used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types .
    Auristatin S
  • HY-P9994
    Pertuzumab zuvotolimod

    SBT6050

    		 Antibody-Drug Conjugates (ADCs) EGFR Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .
    Pertuzumab zuvotolimod
  • HY-176455
    ADC-5 drug-linker

    		Drug-Linker Conjugates for ADC Cancer
    ADC-5 drug-linker (Compound linker-payload 5) is a drug-linker conjugate for ADC with potent anti-tumor activity. ADC-5 drug-linker can be used to synthesize NLRP3 agonist 3 (HY-176452) .
    ADC-5 drug-linker
  • HY-N2493R
    Lawsone (Standard)

    		Reference Standards Fungal Apoptosis Infection Cancer
    Lawsone is an orally active naphthoquinone dye that can be isolated from the leaves of Lawsonia inermis. Lawsone can induce apoptosis. Lawsone has antibacterial, antitumor and antioxidant activities. Lawsone can be used in anti-tumor drug research .
    Lawsone (Standard)
  • HY-W004698
    (2-Methoxypyrimidin-5-yl)boronic acid

    		Drug Intermediate Others
    (2-Methoxypyrimidin-5-yl)boronic acid is a drug intermediate that can serve as a key reactant in the Suzuki-Miyaura coupling reaction, and is used for the synthesis of isoquinoline ketone derivatives with anti-tumor activity .
    (2-Methoxypyrimidin-5-yl)boronic acid
  • HY-170865
    OncoFAP-GlyPro-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    OncoFAP-GlyPro-MMAF is a Drug-Linker Conjugate for ADC with potent antitumor activity. OncoFAP-GlyPro-MMAF consists of Monomethylauristatin F (HY-15579) and a linker. OncoFAP-GlyPro-MMAF can be used for synthesis of ADCs .
    OncoFAP-GlyPro-MMAF
  • HY-179256
    U-031

    		ADC Payload Cancer
    U-031 is an anti-tumor agent. U-031 can be connected to monoclonal antibodies via linkers to form antibody-drug conjugate (ADC) molecules. U-031 is commonly used in cancer research .
    U-031
  • HY-P10239A
    Tyr3-Octreotate acetate

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    Tyr3-Octreotate acetate is a somatostatin analog. Tyr3-Octreotate acetate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate acetate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    Tyr3-Octreotate acetate
  • HY-172497
    DSPE-PEG2000-Mal-Cys-REKA

    		Liposome Cancer
    DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .
    DSPE-PEG2000-Mal-Cys-REKA
  • HY-165606
    SB-T-1214

    		Oct3/4 c-Myc Apoptosis Cancer
    SB-T-1214 (SBT) is a taxane. SB-T-1214 efficiently inhibits expression of stem cell-related genes (Oct4, Sox2, and c-Myc) and induces apoptosis of colon cancer spheroids with drug resistant tumorigenic CD133 +/CD44 + cells. SB-T-1214 strongly represses tumor growth in Pgp+ DLD-1 human colon tumor xenografts mice model. SB-T-1214 can be used for antitumor research, especially against tumors with drug resistance, such as colon, pancreatic and renal cancers .
    SB-T-1214

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: